Neusoft Education Technology : GRANT OF WAIVER UNDER RULE 14.41(a) OF THE LISTING RULES AND DELAY IN DESPATCH OF CIRCULAR

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9616)

GRANT OF WAIVER UNDER RULE 14.41(a) OF THE LISTING RULES

AND

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of Neusoft Education Technology Co. Limited (the "Company") dated 12 April 2021 (the "Announcement"), in relation to the major transaction in relation to the Cooperation Agreement involving the grant of the Call Option to Dalian Education and the announcement of the Company date 30 April 2021 in relation to the delay in despatch of the Circular (the "Delay Announcement"). Unless otherwise specified, capitalized terms used herein shall have the same meanings as those defined in the Announcement and the Delay Announcement.

As stated in the Delay Announcement, since additional time is required to finalize certain information in the Circular, the Company has applied to the Stock Exchange for a waiver from strict compliance with Rule 14.41(a) of the Listing Rules. On 10 May 2021, the Stock Exchange has granted the waiver on condition that the circular would be despatched on or before 21 May 2021. The Stock Exchange may withdraw or change the waiver if the Company's situation changes.

By order of the Board

NEUSOFT EDUCATION TECHNOLOGY CO. LIMITED

Dr. LIU Jiren

Chairperson and non-executive director

Hong Kong, 10 May 2021

As at the date of this announcement, the board of directors comprises Dr. WEN Tao as executive director; Dr. LIU Jiren, Mr. RONG Xinjie, Dr. YANG Li, Dr. ZHANG Yinghui and Mr. Klaus Michael ZIMMER as non-executive directors; and Dr. LIU Shulian, Dr. QU Daokui and Dr. WANG Weiping as independent non-executive directors.